10-Q: Rafael Holdings Q3 2026: Net Loss Widens Amidst R&D Investment

Rafael Holdings reports a wider net loss for the nine months ended April 30, 2026, driven by increased R&D spending, while cash reserves decrease.

Summary

• Rafael Holdings, Inc. reported a net loss attributable to the company of $4.23 million for the three months ended April 30, 2026, compared to a net loss of $4.78 million for the same period in the prior year. For the nine months ended April 30, 2026, the net loss attributable to the company was $20.46 million, an increase from $18.43 million in the prior year.
• Total revenue for the three months ended April 30, 2026, was $179,000, a decrease from $362,000 in the prior year. For the nine months ended April 30, 2026, total revenue was $630,000, an increase from $567,000 in the prior year.
• Cash and cash equivalents decreased to $30.5 million as of April 30, 2026, from $52.8 million as of July 31, 2025.
• The company's primary focus remains on the development of Trappsol Cyclo for Niemann-Pick Disease Type C1 (NPC1).
• A significant gain on settlement of accounts payable and convertible notes payable of $3.72 million was recorded in the current quarter.
• The company has identified a material weakness in internal control over financial reporting at its acquired subsidiary, Cyclo Therapeutics, Inc., related to accruals and expenses.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the widening net loss, decreased revenue in the short term, and significant cash burn, despite positive developments in clinical trials and FDA interactions.

Positives

• A gain of $3.72 million was recognized from the settlement of accounts payable and convertible notes payable during the three months ended April 30, 2026.
• The company expects its current cash and cash equivalents of $30.5 million to be sufficient to meet its obligations for at least the next 12 months.
• The VECTR System from Rafael Medical Devices received FDA substantial equivalence determination for use in minimally invasive ligament or fascia release surgeries.
• The company made progress in its Trappsol Cyclo development, with the last patient completing the final 96-week visit in the pivotal Phase 3 TransportNPC study. Topline results are expected in the second half of calendar 2026.
• A pre-New Drug Application (NDA) meeting with the FDA was completed, with an NDA submission for Trappsol Cyclo expected in the second half of calendar 2026.

Negatives

• The net loss attributable to Rafael Holdings, Inc. increased to $20.46 million for the nine months ended April 30, 2026, from $18.43 million in the prior year.
• Total revenue for the three months ended April 30, 2026, decreased by 50.8% to $179,000 from $362,000 in the prior year.
• Cash and cash equivalents decreased by 42% to $30.5 million as of April 30, 2026, from $52.8 million as of July 31, 2025.
• Research and development expenses in the Healthcare segment increased significantly by 62% to $4.85 million for the three months ended April 30, 2026, and by 236% to $16.86 million for the nine months ended April 30, 2026.
• A material weakness in internal control over financial reporting was identified at Cyclo Therapeutics, Inc., related to accruals and expenses.

Risks

• The company's lead candidate, Trappsol Cyclo, is still in clinical trials, and regulatory approval and market success are not guaranteed.
• The company's ability to continue as a going concern is dependent on its ability to secure additional financing and achieve profitability.
• The company has a history of net losses and significant cash burn, which could impact its ability to fund ongoing operations and development.
• The company is subject to risks associated with its various subsidiaries and investments, including potential impairments and strategic reviews.
• The identified material weakness in internal controls at Cyclo Therapeutics, Inc. could lead to future misstatements if not effectively remediated.

Future Outlook

The company expects its cash and cash equivalents to be sufficient for at least the next 12 months. The primary focus is on advancing Trappsol Cyclo through its pivotal Phase 3 clinical trial towards regulatory approval and market launch. The company also plans to expand its investment portfolio through opportunistic and strategic investments. Topline results for the TransportNPC study are expected in the second half of calendar 2026, with an NDA submission anticipated in the same period.

Management Comments

• The company is currently evaluating its other holdings to ensure the future focus of its resources on core assets and specifically the Trappsol Cyclo clinical and development efforts.
• The company expects that Barer will primarily operate as an entity holding interest in two cancer-focused opportunities.
• The company is currently reviewing Cornerstone's current efforts, prospects and available resources to determine the optimal operational direction.
• The company does not anticipate paying dividends on its common stock until it achieves sustainable profitability and retains certain minimum cash reserves.

Industry Context

StockSavvy.ai notes that Rafael Holdings operates in the highly competitive and capital-intensive biotechnology sector, with a focus on rare diseases. The company's strategy involves advancing its lead candidate, Trappsol Cyclo, while also managing a diverse portfolio of investments. The increased R&D spending aligns with industry trends for companies pursuing novel therapeutics, but also highlights the significant financial risks involved.

Comparison to Industry Standards

• The net loss of $20.46 million for the nine months ended April 30, 2026, is substantial, reflecting the high costs associated with drug development. Many early-stage biotechnology companies experience significant losses before reaching commercialization.
• The company's cash burn rate, as indicated by the decrease in cash and cash equivalents from $52.8 million to $30.5 million, is a critical factor. Companies in this sector often rely on continuous fundraising to sustain operations, and a 12-month cash runway is a common benchmark for assessing near-term viability.
• The focus on a rare disease (NPC1) is a common strategy in the biotechnology sector, as it can lead to expedited regulatory pathways (like Fast Track designation) and potentially premium pricing if successful. However, the market size for rare diseases is inherently smaller.
• The company's diversified portfolio, including interests in LipoMedix, Cornerstone, Rafael Medical Devices, and Day Three, is typical for a holding company structure aiming to spread risk and capitalize on multiple opportunities. However, it also presents challenges in resource allocation and strategic focus.

Corporate Governance

Related Party Transactions

• IDT Corporation provided services to the Company, invoicing approximately $60,000 and $61,000 for the three months ended April 30, 2026 and 2025, respectively, and $217,000 and $221,000 for the nine months ended April 30, 2026 and 2025, respectively. Balances due from IDT were $60,000 and $59,000 as of April 30, 2026 and July 31, 2025, respectively.
• IDT Corporation leases office and parking space from the Company. The Company invoiced IDT approximately $30,000 and $28,000 for the three months ended April 30, 2026 and 2025, respectively, and $89,000 and $84,000 for the nine months ended April 30, 2026 and 2025, respectively. As of April 30, 2026 and July 31, 2025, IDT owed the Company approximately $221,000 and $93,000, respectively.
• Related party rental income represented approximately 13% and 8% of total revenue for the three months ended April 30, 2026 and 2025, respectively, and 13% and 15% for the nine months ended April 30, 2026 and 2025, respectively.
• Howard S. Jonas, Chairman of the Board, entered into a Standby Purchase Agreement related to a rights offering. Related parties of Mr. Jonas purchased approximately $21.0 million of Class B common stock in a private placement.
• Howard S. Jonas holds an indirect investment in NINA Medical Ltd., and collectively with the Company, they are entitled to designate a director. Howard S. Jonas is currently serving as the Seed Director.

Stakeholder Impact

• Shareholders: The increased net loss and decrease in cash may be concerning. However, positive developments in the Trappsol Cyclo clinical trial and FDA interactions offer potential future upside. The rights offering and private placement indicate efforts to secure capital.
• Employees: Stock-based compensation continues to be a significant expense. The company's ability to fund operations impacts job security.
• Creditors: The company settled a significant creditor payable, reducing its liabilities.
• Management: The company is focused on advancing its lead drug candidate, which requires significant investment and carries inherent risks.

Next Steps

• Complete the pivotal Phase 3 clinical trial for Trappsol Cyclo.
• Submit an NDA for Trappsol Cyclo in the second half of calendar 2026.
• Report topline results from the TransportNPC study in the second half of calendar 2026.
• Continue to evaluate other holdings to focus resources on core assets.
• Remediate the material weakness in internal controls at Cyclo Therapeutics, Inc.

Key Dates

Recommendation

The company shows progress in its lead drug candidate's clinical development and has a clear path towards potential regulatory submission. However, the widening net loss, significant cash burn, and identified internal control weaknesses necessitate a cautious approach. A 'hold' recommendation reflects the balance between potential future success and current financial and operational risks.

Keywords

Rafael Holdings, Form 10-Q, Quarterly Report, Trappsol Cyclo, Niemann-Pick Disease, Biotechnology, Clinical Trials, FDA, NDA Submission, Financial Results, Net Loss, Cash Flow, Goodwill Impairment, Internal Controls